Objectives: To review the role of computerized tomography on the diagnosis of intradiverticulum bladder cancer. We present images of various cases and perform a bibliographic review.
Methods: 5 cases of intra-diverticulum bladder cancer were identified after a retrospective review. All cases had pathological confirmation. Radiological findings are reviewed for this technique and compared with those obtained by other diagnostic tests.
Results: CT scan allowed the diagnosis of the disease and its extension. Lateral wall was the most frequent diverticulum location and intra-diverticulum mass was the most frequent clinical presentation. Two patients showed tumor calcification, one in the peripheral area, the other allover the tumor area. Vascular behavior of these tumors is similar to the rest of non intra-diverticulum bladder neoplasms. Two cases showed main lumen involvement as well. All tumors were transitional cell carcinomas.
Conclusions: CT scan is an efficient diagnostic method for the intra-diverticulum carcinoma as well as for extension determination, and it is essential for surgical planning.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Endometriosis-associated primary clear cell adenocarcinoma of the urinary bladder: A case report and literature review.
Urol Case Rep
January 2025
Hackensack University Medical Center, 30 Prospect Avenue, Hackensack, NJ, 07601, USA.
Primary clear cell adenocarcinoma (CCA) of the urinary bladder is a rare and aggressive malignancy. Few reports in the literature describe this presentation, as associated with malignant transformation of endometriosis. This case highlights the complex etiology of this variant of CCA, initially diagnosed using comprehensive imaging and genetic analysis, and subsequently confirmed through extensive surgical intervention and chemotherapy.
View Article and Find Full Text PDFNeuroendocrine tumour of the urinary bladder.
BMJ Case Rep
January 2025
Royal Derby Hospital, Derby, UK.
We report a rare case of urinary bladder neuroendocrine tumour (NET) in a young, non-smoking man. He had no known risk factors and no comorbidities. After being diagnosed with a bladder tumour while being investigated for flank pain and poor renal function, he was treated with transurethral resection of the bladder tumour and deroofing of ureters bilaterally.
View Article and Find Full Text PDFMolecular profiling of bladder cancer xenografts defines relevant molecular subtypes and provides a resource for biomarker discovery.
Transl Oncol
January 2025
Johns Hopkins Greenberg Bladder Cancer Institute, Brady Urological Institute, Johns Hopkins University, Baltimore, MD, USA. Electronic address:
Bladder cancer (BLCA) genomic profiling has identified molecular subtypes with distinct clinical characteristics and variable sensitivities to frontline therapy. BLCAs can be categorized into luminal or basal subtypes based on their gene expression. We comprehensively characterized nine human BLCA cell lines (UC3, UC6, UC9, UC13, UC14, T24, SCaBER, RT4V6 and RT112) into molecular subtypes using orthotopic xenograft models.
View Article and Find Full Text PDFRandomized Comparison of Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Results From the Prospective BladderPath Trial.
J Clin Oncol
January 2025
Institute of Cancer Research, London, United Kingdom.
Purpose: Transurethral resection of bladder tumor (TURBT) is the initial staging procedure for new bladder cancers (BCs). For muscle-invasive bladder cancers (MIBCs), TURBT may delay definitive treatment. We investigated whether definitive treatment can be expedited for MIBC using flexible cystoscopic biopsy and multiparametric magnetic resonance imaging (mpMRI) for initial staging.
View Article and Find Full Text PDFClinical outcome of BCG treatment for patients with urothelial carcinoma of the prostatic urethra: Implications for early cystectomy.
World J Urol
January 2025
Department of Urology, Saint Marianna University School of Medicine, Kawasaki, Japan.
Purposes: This study aimed to clarify the clinical outcomes of Bacillus Calmette-Guérin (BCG) treatment in patients with urothelial carcinoma (UC) of the prostatic urethra.
Methods: Between August 2003 and January 2023, 428 patients with non-muscle-invasive UC received BCG treatment (Tokyo strain, 80 mg, ≥ 5 times) in our hospital; 39 had UC of the prostatic urethra. We evaluated the cumulative incidence of intravesical recurrence, progression (muscle-invasive bladder cancer [MIBC] or metastasis), and subsequent radical cystectomy after BCG treatment in patients with UC of the prostatic urethra.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!